Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The acetylcholine receptor subunit alpha 1 (nAChRα1) is a key component of muscle-type nicotinic acetylcholine receptors (nAChRs). These receptors mediate fast synaptic transmission at neuromuscular junctions. The nAChRα1 subunit, encoded by the CHRNA1 gene, forms part of a pentameric receptor complex. Binding of acetylcholine to the α1 subunit triggers a conformational change, opening an ion channel and enabling cation influx (Na+, K+, Ca2+), resulting in membrane depolarization and muscle contraction. Mutations in CHRNA1 are associated with congenital myasthenic syndromes. Furthermore, nAChRα1 is the target of autoantibodies in myasthenia gravis.
Agonist-induced channel opening leading to cation influx and membrane depolarization; Competitive antagonism leading to channel blockade.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cholinergic receptor nicotinic alpha 1 subunit (nAChRα1).